FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Jan. 23, 2006--Andrx Corporation (Nasdaq:ADRX) (“Andrx” or the “Company”) announced today that it has entered into an agreement with InvaGen Pharmaceuticals Inc. (“InvaGen”) to commercialize 11 abbreviated new drug applications (ANDA), which, according to IMS data, had total brand sales exceeding $13 billion for the trailing 12 months ended September 2005. ANDAs for two of the products have been filed with the U.S. Food and Drug Administration (“FDA”) and it is anticipated the ANDAs for the remaining products will be submitted during 2006 and through early 2007.
